Literature DB >> 849359

Correlation between levels of breakdown products of C3, C4, and properdin factor B in synovial fluids from patients with rheumatoid arthritis.

L H Perrin, U E Nydegger, R H Zubler, P H Lambert, P A Miescher.   

Abstract

Synovial fluids from 31 patients with seropositive rheumatoid arthritis (RA) and 23 patients with seronegative RA had significantly increased levels of breakdown products to C3, C4, and properdin factor B when compared to patients with osteoarthritis (OA) (P less than 0.01). The same patients exhibited a considerable overlap of native C3, C4, and properdin factor B levels when their results were compared with those of OA patients. The parallel increase of C3d, C4d, and Ba levels in patients with RA suggests an activation of the complement system rather than a nonspecific enzymatic breakdown in synovial fluids.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 849359     DOI: 10.1002/art.1780200202

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  17 in total

1.  Absence of IgA nephropathy in patients with ankylosing spondylitis.

Authors:  A J Swaak; I Frankfort; R S Menon; J M Pekelharing; O Planten
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

2.  Complement (C3) metabolism in rheumatoid arthritis in relation to the disease course.

Authors:  A J Swaak; H Han; A van Rooyen; M Pillay; C E Hack
Journal:  Rheumatol Int       Date:  1988       Impact factor: 2.631

3.  Evaluation of plasma C3d and immune complex determinations in the assessment of disease activity of patients with rheumatoid arthritis, systemic lupus erythematosus, and spondylitis ancylopoetica.

Authors:  P B Krauledat; F E Krapf; B Manger; J R Kalden
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

4.  Complement activating properties of complexes containing rheumatoid factor in synovial fluids and sera from patients with rheumatoid arthritis.

Authors:  C J Elson; S D Carter; B J Cottrell; D G Scott; P A Bacon; T B Wallington
Journal:  Clin Exp Immunol       Date:  1985-02       Impact factor: 4.330

5.  Determination of the half-life of C3 in patients and its relation to the presence of C3-breakdown products and/or circulating immune complexes.

Authors:  A J Swaak; A Hannema; C Vogelaar; F A Boom; L van Es; R van Aalst; L W Statius van Eps
Journal:  Rheumatol Int       Date:  1982       Impact factor: 2.631

6.  High levels of complement breakdown products in tuberculous pleural effusions.

Authors:  D P Lew; L H Perrin; J D Vassalli; S Suter; P H Lambert; F A Waldvogel
Journal:  Clin Exp Immunol       Date:  1983-06       Impact factor: 4.330

7.  The use of C3d as a means of monitoring clinical activity in systemic lupus erythematosus and rheumatoid arthritis.

Authors:  W J Morrow; D J Williams; C Ferec; R Casburn-Budd; D A Isenberg; E Paice; M L Snaith; P Youinou; P Le Goff
Journal:  Ann Rheum Dis       Date:  1983-12       Impact factor: 19.103

8.  Correlation of disease activity with circulating immune complexes (C1qbA) and complement breakdown products (C3D) in patients with systemic lupus erythematosus. A prospective study.

Authors:  A J Swaak; J Groenwold; A Hannema; C E Hack
Journal:  Rheumatol Int       Date:  1985       Impact factor: 2.631

9.  Complement (C3) metabolism in systemic lupus erythematosus in relation to the disease course.

Authors:  A J Swaak; A van Rooyen; C Vogelaar; M Pillay; E Hack
Journal:  Rheumatol Int       Date:  1986       Impact factor: 2.631

10.  Isolation and analysis of complement activating aggregates from synovial fluid of patients with rheumatoid arthritis using monoclonal anti-C3d antibodies.

Authors:  A E Bedwell; C J Elson; S D Carter; P A Dieppe; C W Hutton; R Czudek
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.